| Entry |
|
|---|
| Name |
Aclidinium bromide (JAN/USAN/INN);
Tudorza pressair (TN);
Eklira genuair (TN)
|
|---|
| Product |
|
|---|
| Formula |
C26H30NO4S2. Br
|
|---|
| Exact mass |
563.08
|
|---|
| Mol weight |
564.5547
|
|---|
| Structure |
   |
|---|
| Class |
Neuropsychiatric agent
DG01491 Muscarinic cholinergic receptor antagonist
Metabolizing enzyme substrate
DG02973 BCHE substrate
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG01522 CYP3A4 inhibitor
DG01915 CYP3A5 inhibitor
|
|---|
| Remark |
| Therapeutic category: | 2259 |
|
|---|
| Efficacy |
Bronchodilator, Muscarinic acetylcholine receptor antagonist |
|---|
| Disease |
Chronic obstructive pulmonary disease [DS: H01714] |
|---|
| Comment |
Quaternary ammonium compound
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
|
|---|
| Interaction |
CYP inhibition: CYP2D6 [HSA: 1565], CYP3A4 [HSA: 1576], CYP3A5 [HSA: 1577]
 |
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
R RESPIRATORY SYSTEM
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03BB Anticholinergics
R03BB05 Aclidinium bromide
D08837 Aclidinium bromide (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Bronchodilators, Anticholinergic
Aclidinium
D08837 Aclidinium bromide (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
22 Respiratory organ agents
225 Bronchodilators
2259 Others
D08837 Aclidinium bromide (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Acetylcholine (muscarinic)
CHRM
D08837 Aclidinium bromide (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D08837
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08837
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D08837
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D08837
 |
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 34
1 C1d C 23.0773 -15.4815
2 C8y C 23.0773 -14.0754
3 C7a C 21.8117 -16.1847
4 O7a O 20.6165 -15.4815
5 O6a O 21.8117 -17.5908
6 C1y C 19.4214 -16.1847
7 C1y C 18.1559 -15.4815
8 C1x C 19.4214 -17.6611
9 C1x C 16.8903 -16.1847
10 C1x C 18.5777 -16.7471
11 N2y N 18.1559 -18.3642 #+
12 C1x C 16.8903 -17.5908
13 C1x C 17.7339 -16.9580
14 O1a O 24.2725 -14.7785
15 C1b C 18.1559 -19.7703
16 C8x C 24.2149 -13.2489
17 C8x C 23.7804 -11.9116
18 C8x C 22.3743 -11.9116
19 S2x S 21.9398 -13.2489
20 C1b C 16.9381 -20.4734
21 C1b C 15.7373 -19.7799
22 O2a O 14.5447 -20.4684
23 C8y C 13.3483 -19.7774
24 C8x C 13.3483 -18.3644
25 C8x C 12.1306 -17.6613
26 C8x C 10.9129 -18.3644
27 C8x C 10.9128 -19.7773
28 C8x C 12.1305 -20.4805
29 C8y C 24.0532 -16.7238
30 C8x C 24.5155 -18.0413
31 C8x C 25.9112 -18.0087
32 C8x C 26.3117 -16.6712
33 S2x S 25.1634 -15.8771
34 X Br 11.7579 -13.5833 #-
BOND 37
1 1 2 1
2 1 3 1
3 3 4 1
4 3 5 2
5 6 4 1 #Up
6 6 7 1
7 6 8 1
8 7 9 1
9 7 10 1
10 8 11 1
11 9 12 1
12 10 13 1
13 11 12 1
14 11 13 1
15 1 14 1
16 11 15 1
17 2 16 2
18 16 17 1
19 17 18 2
20 18 19 1
21 2 19 1
22 15 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 23 24 2
27 24 25 1
28 25 26 2
29 26 27 1
30 27 28 2
31 23 28 1
32 29 30 2
33 30 31 1
34 31 32 2
35 32 33 1
36 29 33 1
37 1 29 1
|
|---|
